Navigation Links
deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court

REYKJAVIK, Iceland, November 24 /PRNewswire-FirstCall/ -- deCODE genetics, Inc. (Nasdaq:DCGN) today announced the approval of all of its "first day" motions by the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). deCODE last week filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code with the Bankruptcy Court.

The orders issued by the Bankruptcy Court allow the company to continue to operate its business during the Chapter 11 proceedings. In particular, the company received interim Bankruptcy Court approval of its previously-announced debtor-in-possession financing from Saga Investments, LLC, the "stalking horse" bidder for deCODE's Iceland-based genetics subsidiary. The subsidiary conducts deCODE's human genetics research, manages its population genetics resources, and provides its personal genome scans, DNA-based risk assessment tests and genomics services for contract customers. The funding provided by this agreement will be used to support deCODE and its Icelandic subsidiary's operations and full range of products and services through the conclusion of the Bankruptcy Court-supervised sale process.

About deCODE

deCODE is a global leader in analysing and understanding the human genome. deCODE has identified key variations in the sequence of the genome conferring increased risk of major public health challenges from cardiovascular disease to cancer, and employs its gene discovery engine to develop DNA-based tests to assess individual risk of common diseases; to license its tests and intellectual property to partners; and to provide comprehensive, leading- edge contract services to companies and research institutions around the globe. Through its CLIA- and CAP-certified laboratory deCODE offers DNA-based tests for gauging risk and empowering prevention of common diseases, including deCODE T2(TM) for type 2 diabetes; deCODE AF(TM) for atrial fibrillation and stroke; deCODE MI(TM) for heart attack; deCODE ProstateCancer(TM) for prostate cancer; deCODE Glaucoma(TM) for a major type of glaucoma; and deCODE BreastCancer, for the common forms of breast cancer. Through its pioneering personal genome analysis service deCODEme(TM), deCODE enables individuals to better understand their risk of dozens of common diseases and to learn about their ancestry and other traits. Visit us on the web at; at; at; and on our blog at

Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding deCODE's expectations concerning the bankruptcy process and the continuation of day-to-day operations. deCODE's actual results could differ materially from those anticipated in the forward-looking statements as a result of risks and uncertainties, including, without limitation, (1) the impact of the announcement of its bankruptcy filing on deCODE's operations; (2) the ability of deCODE to maintain sufficient debtor-in-possession financing to fund its operations and the expenses of the Chapter 11 proceeding; (3) the ability of deCODE to obtain court approval of its motions in the Chapter 11 proceeding; (4) the outcome and timing of the proposed sale of deCODE's assets, including deCODE's ability to close a transaction with SagaInvestments, LLC or any other purchaser; (5) the uncertainty associated with motions by third parties in the bankruptcy proceeding; (6) deCODE's ability to obtain and maintain normal terms with vendors and service providers and contracts that are critical to its operation; and (7) other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10-K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. deCODE undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.


    deCODE genetics
    Joy Bessenger        Edward Farmer       Gisli Arnason
    +1-212-481-3891      +354-570-2819       +354-570-1900

SOURCE DeCODE Genetics Inc

Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Amaizing: Corn genome decoded
2. deCODE Receives Nasdaq Bid Price Deficiency Notice
3. deCODE genetics Announces Second Quarter 2009 Financial Results
4. deCODE genetics Announces Webcast of Conference Call to Discuss Second Quarter 2009 Financial Results
5. Its Not Just the Sun: deCODE Discovers Sequence Variants Affecting Susceptibility to Skin Cancer
6. deCODE Discovers a Gene Linked to Risk of Kidney Stones and Osteoporosis
7. deCODE Reinstated to Nasdaq Global Market
8. deCODE Genotyping Laboratory Receives College of American Pathologists Accreditation
9. deCODE Study Shows Complex Interplay of the Human Biological Clock With Height, Weight and Disease
10. deCODE genetics Announces First Quarter 2009 Financial Results
11. deCODE genetics Announces Webcast of Conference Call to Discuss First Quarter 2009 Financial Results
Post Your Comments:
(Date:11/30/2015)... DIEGO , Nov. 30, 2015  HUYA Bioscience ... China,s pharmaceutical innovations, today announced it ... Drug Development Fund (KDDF) to foster collaboration between KDDF ... development and commercialization of healthcare products for the global ... as an important source of new innovative preclinical and ...
(Date:11/30/2015)... CA (PRWEB) , ... November ... ... Intelligence Company, today announced tighter software integration with MarkLogic, the Enterprise NoSQL ... organizations maximize information to drive change. , Smartlogic’s Content Intelligence capabilities provide ...
(Date:11/27/2015)... November 27, 2015 ... popularity of companion diagnostics is one of ... market with pharmaceutical companies and diagnostic manufacturers ... tests. . --> ... report on global cancer biomarkers market spread ...
(Date:11/25/2015)... 2 nouvelles études permettent d ... différences entre les souches bactériennes retrouvées dans la plaque ... humains . Ces recherches  ouvrent une nouvelle ... charge efficace de l,un des problèmes de santé ... .    --> 2 nouvelles études permettent d ...
Breaking Biology Technology:
(Date:11/17/2015)... -- Paris , qui s,est ... Paris , qui s,est tenu du 17 ... de l,innovation biométrique, a inventé le premier scanner couplé, ... la même surface de balayage. Jusqu,ici, deux scanners étaient ... empreintes digitales. Désormais, un seul scanner est en mesure ...
(Date:11/12/2015)... , Nov. 12, 2015  A golden retriever ... Duchenne muscular dystrophy (DMD) has provided a new lead ... Children,s Hospital, the Broad Institute of MIT and Harvard ... Brazil . Cell, pinpoints ... dogs "escape" the disease,s effects. The Boston Children,s lab ...
(Date:11/10/2015)... , Nov. 10, 2015  In ... on the basis of product, type, application, ... included in this report are consumables, services, ... report are safety biomarkers, efficacy biomarkers, and ... this report are diagnostics development, drug discovery ...
Breaking Biology News(10 mins):